Editor’s note: A livestream of this event is embedded below.
It’s been almost a decade since the first stunning data on a cell therapy that battled blood cancer by genetically altering a patient’s own white blood cells to attack it. Many years and billions of dollars in mergers and acquisitions later, CAR-T is still used mostly as a last resort. Could new clinical trials that are about to report out in full change that? STAT gathers experts to look ahead.
- Sponsor Introduction: Anshul Mangal, president, Project Farma and Precision ADVANCE
- Daina Graybosch, Ph.D., senior research analyst at SVB Leerink
- Adam Feuerstein, senior writer, biotech, STAT (moderator)